Betta

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

Retrieved on: 
Wednesday, February 28, 2024

Merus also continues to evaluate patients with untreated advanced PD-L1+ HNSCC treated with petosemtamab 1500 mg in combination with pembrolizumab.

Key Points: 
  • Merus also continues to evaluate patients with untreated advanced PD-L1+ HNSCC treated with petosemtamab 1500 mg in combination with pembrolizumab.
  • Merus plans to report initial interim efficacy and safety data from this cohort in the second quarter of 2024.
  • Merus achieved a milestone and received a payment of $2.5 million related to the advancement of this program in the third quarter of 2023.
  • Merus also achieved an additional milestone of $1 million for candidate nomination in the fourth quarter of 2023.

NICE Selected by DiDi Global to Deliver Real-time AI Driven Personalized Interactions

Retrieved on: 
Tuesday, February 27, 2024

NICE (Nasdaq: NICE) today announced that DiDi Global has selected NICE Workforce Management (WFM) and Employee Engagement Manager (EEM) for its cloud-based innovative technology.

Key Points: 
  • NICE (Nasdaq: NICE) today announced that DiDi Global has selected NICE Workforce Management (WFM) and Employee Engagement Manager (EEM) for its cloud-based innovative technology.
  • Betta, responsible for supporting one of the largest WFM customer bases globally, has partnered with NICE Value Realization Services during implementation to execute integrations and deliver consultation, training, and support services in multiple countries.
  • DiDi Global searched for a workforce management solution that would address its core business, functional, and technical requirements while being scalable to support growth.
  • Caio Poli, International Customer Experience Executive Director, DiDi Global, said, “NICE was the clear choice based upon multiple factors.

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

Retrieved on: 
Thursday, January 4, 2024

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the closing of the previously announced $25 million stock purchase agreement with a wholly-owned subsidiary of Betta Pharmaceuticals Co. Ltd (Betta) (300558.SZ), a leading pharmaceutical company focusing on the development of innovative oncology therapies in China.

Key Points: 
  • WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the closing of the previously announced $25 million stock purchase agreement with a wholly-owned subsidiary of Betta Pharmaceuticals Co. Ltd (Betta) (300558.SZ), a leading pharmaceutical company focusing on the development of innovative oncology therapies in China.
  • This investment was completed at $4.49 per share.
  • The purchase price represents a 25% premium over the 60-trading-day volume weighted average through the date that was two business days prior to the entry into the stock purchase agreement on May 29, 2023.

Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update

Retrieved on: 
Thursday, November 2, 2023

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the third quarter and provided a business update.

Key Points: 
  • In the planned trial, patients will be randomized to petosemtamab monotherapy or investigators’ choice of single agent chemotherapy or cetuximab.
  • Merus also continues to enroll patients with previously untreated advanced PD-L1+ HNSCC with petosemtamab 1500 mg in combination with Keytruda®.
  • Initial safety data from this single arm cohort may support the initiation of a first-line registration trial with this combination.
  • Merus achieved a milestone and received a payment of $2.5 million related to the advancement of this program in the third quarter of 2023.

Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update

Retrieved on: 
Monday, August 7, 2023

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the second quarter and provided a business update.

Key Points: 
  • In April, Merus provided an interim clinical update at the American Association for Cancer Research (AACR) Annual Meeting 2023.
  • Merus plans to provide initial clinical data on Zeno in CRPC in the second half of 2023.
  • The Company plans to provide an initial clinical data update from the expansion cohorts, and a further clinical development strategy update in the second half of 2023.
  • In July 2023, Merus achieved a milestone and expects a payment of $2.5 million related to the advancement of this program in the third quarter of 2023.

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

Retrieved on: 
Tuesday, May 30, 2023

WATERTOWN, Mass. and HANGZHOU, China, May 30, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, and Betta Pharmaceuticals Co. Ltd (Betta) (SZ300558), a leading pharmaceutical company focusing on the development of innovative oncology therapies in China, today announced an exclusive licensing agreement for the development and commercialization of CFT8919 in Greater China (including Hong Kong SAR, Macau SAR and Taiwan). CFT8919 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against EGFR L858R for non-small cell lung cancer (NSCLC) patients.

Key Points: 
  • CFT8919 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against EGFR L858R for non-small cell lung cancer (NSCLC) patients.
  • “We are excited to partner with Betta to develop CFT8919, an orally bioavailable allosteric EGFR L858R degrader, with the potential to treat NSCLC patients with EGFR L858R mutations in Greater China and beyond,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics.
  • In China, approximately 693,000 patients were diagnosed with NSCLC in 2020 and approximately 40% of these cases are driven by the EGFR mutation.
  • The L858R mutation is the second most common EGFR mutation, found in approximately 40% of NSCLC patients with EGFR mutations in China.

Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update

Retrieved on: 
Thursday, May 4, 2023

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter and provided a business update.

Key Points: 
  • In April, Merus provided an interim clinical update at the AACR Annual Meeting 2023.
  • Merus plans to provide an update in Q3 2023 on the potential registrational path for this program.
  • In April, Merus provided a pre-clinical presentation of MCLA-129 in comparison with amivantamab at the AACR Annual Meeting 2023.
  • The Company plans to provide an initial clinical data update from the expansion cohorts, and a further clinical development strategy update in the second half of 2023.

Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023

Retrieved on: 
Tuesday, March 14, 2023

The abstract and presentation describe the mechanism of action of MCLA-129, an antibody-dependent cellular cytotoxicity (ADCC) enhanced Biclonics® that targets epidermal growth factor receptor (EGFR) and c-MET in non-small cell lung cancer (NSCLC) and other solid tumors in comparison to the EGFR x c-MET bispecific antibody amivantamab.

Key Points: 
  • The abstract and presentation describe the mechanism of action of MCLA-129, an antibody-dependent cellular cytotoxicity (ADCC) enhanced Biclonics® that targets epidermal growth factor receptor (EGFR) and c-MET in non-small cell lung cancer (NSCLC) and other solid tumors in comparison to the EGFR x c-MET bispecific antibody amivantamab.
  • MCLA-129 is a Biclonics® common light chain bispecific antibody with multiple mechanisms of action, including inhibition of EGFR and c-MET ligand binding, which is observed in preclinical assays to have antibody-dependent cellular phagocytosis and ADCC comparable or more potent than amivantamab.
  • Title: Preclinical evaluation of MCLA-129, a bispecific antibody targeting EGFR and c-MET on solid tumor cells, in comparison with amivantamab
    The full abstract is available on the AACR website .
  • The poster will be available on the Merus website at the start of the session.

Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update

Retrieved on: 
Tuesday, February 28, 2023

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the fourth quarter and full year and provided a business update.

Key Points: 
  • Further, Merus is evaluating Zeno in combination with an ADT (enzalutamide or abiraterone) in men with CRPC, irrespective of NRG1+ status.
  • Merus plans to provide initial clinical data on Zeno in CRPC in the second half of 2023.
  • Merus plans to provide a clinical update on petosemtamab in the first half of 2023 at a medical conference.
  • In the fourth quarter of 2022, Merus achieved a milestone payment of €1.0 million from Ono for preclinical advancement of a lead candidate arising from this license.

CORRECTING and REPLACING --Merus Provides 2023 Outlook

Retrieved on: 
Monday, January 9, 2023

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today provided its 2023 outlook.

Key Points: 
  • The corrected release follows:
    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today provided its 2023 outlook.
  • “2023 looks to be another productive year for Merus with multiple value-creating clinical updates throughout the year.
  • Merus plans to provide an initial clinical data update on Zeno in CRPC in the second half of 2023.
  • Merus plans to provide a clinical update for petosemtamab at a medical conference in the first half of 2023.